Antiphospholipid antibody syndrome

Journal of Association of Physicians of India

Volumn 58, Issue 3, 2010, Pages 176-184

  Saigal, Renu ^a   Kansal, Amit ^a   Mittal, Manoop ^a   Singh, Yadvinder ^a   Ram, Hari ^a  

^a SMS MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLASSIFICATION; HUMAN; IMMUNOLOGY; THROMBOSIS; COMPLICATION;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; THROMBOSIS; WARFARIN;

EID: 77649166498     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Lockshine MD. Update on antiphospholipid syndrome. Bull Hosp Jt Dis 2006; 64(1-2): 57-9
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346(10):752-63.
3. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15(2):145-51.
4. Gezer S. Antiphospholipid syndrome. Dis Mon 2003;49(12):696-741.
5. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019-27.
6. Bick RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003; 17(1):115-47.
7. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
8. Walenga J, Michal K, Hoppensteadt D, et al. Vascular damage correlates between heparininduced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 1999;5(Suppl 1):S76
9. Takeuchi R, Atsumi T, Ieko M, et al. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781.
10. Koike T, Bohgaki M, Amengual O, et al. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28(23):129-33.
11. Hanly J, Smith S. Anti-beta2-glycoprotein I (GPI) autoantibodies annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000;120:537.
12. Di Simone N, Castellani R, Caliandro D, et al. Antiphospholipid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 2002;77:805.
13. Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 2005; 1051: 413-20.
14. Wilson W, Gharavi A, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-11.
15. Lockshine MD. Update on antiphospholipid syndrome. Bull Hosp Jt Dis 2006; 64(1-2): 57-9
16. Bick R, Baker W. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999;25:333-50.
17. Ames PR, Margarita A, Sokoll KB, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64(2):315-7.
18. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005; 20: 105-12.
19. Brey RL. Management of the neurological manifestations of APS- What do the trials tell us? Thromb Res 2004;114(5-6):489-99.
20. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci 2005;1051:465-86.
21. Rand JH. The antiphospholipid syndrome. In: Beutler E, editor. Williams hematology. 6th edition. New York: McGraw-Hill; 2001. p. 1715-33.
22. Lockshine MD. Update on antiphospholipid syndrome. Bull Hosp Jt Dis 2008; 66(3): 195-7
23. WF Baker, RL Bick. The clinical spectrum of Antiphospholipid syndrome. Hematol Oncol Clin North Am 2008;22:33-52
24. Toubi E, Krause I, Fraser A, et al. Livedo reticularis as a marker for predicting multisystem thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005;23:499-504.
25. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006; 5: 344-8.
26. Asherson RA, Cervera R, Wells AU. Diffuse alveolar hemorrhage: a nonthrombotic antiphospholipid lung syndrome? Semin Arthritis Rheum 2005; 35: 138-42.
27. Uthman I, Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum 2006; 35: 360-7.
28. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology 2007;46:1641-1647
29. Uthman I, Salti I, Khamashta M. Endocrinologic manifestations of the antiphospholipid syndrome. Lupus 2006; 15: 485-9.
30. Piette JC, Cervera R, Levy RA, et al. The catastrophic antiphospholipid syndrome-Asherson's syndrome. Ann Med Interne (Paris) 2003;154:195-6.
31. Asherson RA. Catas t rophic ant iphosphol ipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4.
32. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: Where do we stand? Arthritis Rheum 2003;48(12):3320-7.
33. Bucciarelli S, Cervera R, Espinosa G, Gomez-Puerta JA, Ramos-Casals M, Font J. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmun Rev 2006; 6: 72-5.
34. Pierangeli S, Gharavi A, Harris EN. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun 2000;15:241
35. Asherson RA. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev 2006;6(2):76-80.
36. Musa M, Nounou R, Sahovic E, et al. Fulminant thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus and phospholipid autoantibodies. Eur J Haematol 2000;64:433-5.
37. Fritsma GA, Marques MB. Thrombosis risk testing. In: Rodah BF, Fritsma GA, Doig K, editors. Hematology: clinical principles and applications. St. Louis (MO): Saunders Elsevier; 2007. p. 605-28.
38. Asherson R, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003;62:388-93.
39. Asherson R, Cervera R, Piette JC. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-77.
40. Triolo G, Ferrante A, Ciccia F et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis & Rheumatism 2003; 48: 728-731.
41. Branch DW, Peaceman AM, Druzin M et al. A multicenter, placebocontrolled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. American Journal of Obstetrics and Gynecology 2000; 182: 122-127.
42. Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006;32:591-607.
43. Pauzner R, Dulitzki M, Lanevitz P et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thrombosis and Haemostasis 2001; 86: 1379-1384.
44. Ostensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis research & therapy 2006; 8: 209. (Epub 2006 May 11).
45. Erkan D, Sammaritano L, Levy R, et al. APLASA study 2004 update: primary thrombosis prevention in asymptomatic aPL-positive patients with aspirin [abstract]. Arthritis Rheum 2004; 50(9):S640-1.
46. Cooper C, Choy E. The blossoming of evidence-based clinical rheumatology: The Arthritis Research Campaign's Clinical Trials Collaboration in association with the MRC. Clinical Trials Unit, BSR and BOA. Rheumatology (Oxford) 2003;42(6):713-5.
47. Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literature and management strategies. Curr Rheumatol Rep 2002;4(5):379-86.
48. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133-8
49. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
50. Erkan D, Lockshin MD. New treatments for antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32: 129-48.
51. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez- Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004; 31: 1560-7.
52. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with war farin for prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349:1703-12.
53. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293(6):681-9.
54. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349(18): 1713-21.
55. Astrazeneca receives action letter from FDA for Exanta (Ximelagatran) (newsletter). Available at: http://www.astrazeneca.com/pressrelease/3285.aspx. Accessed June 22, 2005.
56. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050-7.